Journal Watch · Frontiers in Immunology · 2026

Integrated multi-omics analysis unveils microbiota-metabolite-host interactions and novel biomarkers for early diabetic kidney disease diagnosis.

Nevertheless, further studies are required to validate the identified associations and confirm their clinical applicability in real-world East Asian settings.

Jiang T, Deng J, Hu X et al.Frontiers in Immunology4 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1781013PMID: 41878445Study type: cohort / observational clinical study

TL;DR

Nevertheless, further studies are required to validate the identified associations and confirm their clinical applicability in real-world East Asian settings.

Key findings

  • Metabolomic profiling demonstrated alterations in branched-chain amino acids (BCAAs) and fatty acids.
  • Integrated multi-omics analysis suggested complex interactions among microbiota and metabolites that may contribute to DKD progression.
  • The ML models achieved an accuracy exceeding 90% in distinguishing T2DM from DKD in the East Asian cohort.<h4>Conclusion</h4>Multi-omics integration combined with ML may provide candidate biomarkers for the early detection of DKD in the East Asian population.
  • These approaches could improve the accuracy of non-invasive diagnosis and support the development of personalized management strategies.
  • Nevertheless, further studies are required to validate the identified associations and confirm their clinical applicability in real-world East Asian settings.

Numbers at a glance (from the abstract)

n = 53560%90%2.5-fold

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Clinical samples (n = 535) were collected from East Asian individuals and analyzed for microbiota composition, metabolomic profiling, and TIFs. Subsequently, ML models were constructed to differentiate patients with T2DM from those with DKD in this cohort.<h4>Results</h4>MR analysis identified significant associations between specific microbiota taxa (e.g., Haemophilus-A, TM7x, Lachnoanaerobaculum, and Bacteroides) and metabolites (e.g., tyrosine and glutamine) in relation to DKD within the East Asian cohort. However, the causal nature of these associations requires further experimental or longitudinal validation. Clinical analyses revealed microbial dysbiosis in patients with DKD, including a 2.5-fold increase in Klebsiella and a 60% reduction in Faecalibaculum and Dubosiella.

Full abstract (original)

Background: <h4>Background</h4>Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD), and its early diagnosis remains a major global challenge because conventional biomarkers lack sensitivity. The East Asian population is characterized by distinct genetic, environmental, and lifestyle factors that may influence the development and progression of DKD, highlighting the importance of population-specific research. The primary objective of this study was to apply a multi-omics strategy, including Mendelian randomization (MR) analysis, within an East Asian cohort to investigate potential causal relationships among microbiota, metabolites, and DKD, with the aim of identifying candidate biomarkers relevant to this population. Secondary objectives included the analysis of clinical samples from East Asian participants to characterize microbiota composition, metabolomic profiles, and tongue image features (TIFs), as well as the development of machine learning (ML) models to distinguish patients with type 2 diabetes mellitus (T2DM) from those with DKD.<h4>Methods</h4>MR analysis was performed to investigate potential causal associations between more than 190 microbiota taxa and 404 differential metabolites in relation to DKD within the East Asian cohort.

What they did: Clinical samples (n = 535) were collected from East Asian individuals and analyzed for microbiota composition, metabolomic profiling, and TIFs. Subsequently, ML models were constructed to differentiate patients with T2DM from those with DKD in this cohort.<h4>Results</h4>MR analysis identified significant associations between specific microbiota taxa (e.g., Haemophilus-A, TM7x, Lachnoanaerobaculum, and Bacteroides) and metabolites (e.g., tyrosine and glutamine) in relation to DKD within the East Asian cohort. However, the causal nature of these associations requires further experimental or longitudinal validation. Clinical analyses revealed microbial dysbiosis in patients with DKD, including a 2.5-fold increase in Klebsiella and a 60% reduction in Faecalibaculum and Dubosiella.

Results & conclusions: Metabolomic profiling demonstrated alterations in branched-chain amino acids (BCAAs) and fatty acids. Integrated multi-omics analysis suggested complex interactions among microbiota and metabolites that may contribute to DKD progression. The ML models achieved an accuracy exceeding 90% in distinguishing T2DM from DKD in the East Asian cohort.<h4>Conclusion</h4>Multi-omics integration combined with ML may provide candidate biomarkers for the early detection of DKD in the East Asian population. These approaches could improve the accuracy of non-invasive diagnosis and support the development of personalized management strategies. Nevertheless, further studies are required to validate the identified associations and confirm their clinical applicability in real-world East Asian settings.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1781013 · PubMed 41878445.

Why it matters for pharma & biotech

  • Directly relevant to teams in AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: AI in drug discovery / diagnostics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

Nevertheless, further studies are required to validate the identified associations and confirm their clinical applicability in real-world East Asian settings.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Clinical samples (n = 535) were collected from East Asian individuals and analyzed for microbiota composition, metabolomic profiling, and TIFs.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1781013. PubMed ID: 41878445. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Jiang T, Deng J, Hu X et al.. Integrated multi-omics analysis unveils microbiota-metabolite-host interactions and novel biomarkers for early diabetic kidney disease diagnosis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1781013.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/integrated-multi-omics-analysis-unveils-microbiota-metabolite-host-inter-781013/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides